### 2024 Health Care Affordability State Policy Snapshot

# MARYLAND

CURB EXCESS PRICES IN THE SYSTEM	PREMIUM RATE REVIEW	HEALTH CARE SPENDING BENCHMARKS	HOSPITAL PRICE REGULATION	PUBLIC OPTION
IMPROVE OVERSIGHT, ACCOUNTABILITY AND TRANSPARENCY	HEALTH SPENDING OVERSIGHT ENTITIES	ALL-PAYER OR MULTI-PAYER CLAIMS DATABASE	PRICE TRANSPARENCY	MEDICAL DEBT COLLECTION REGULATIONS
ADDRESS CONSOLIDATION AND PROMOTE COMPETITION	CONSOLIDATION ASSESSMENT AND AUTHORIZATION	BALANCE BILL PROTECTIONS	FACILITY FEE LIMITS	ANTI- COMPETITIVE CONTRACT PROVISIONS
MAKE OUT-OF-POCKET COSTS AFFORDABLE	REDUCED COST-SHARING: PRESCRIPTION DRUGS	REDUCED COST-SHARING: HIGH VALUE SERVICES	MEDICAL DEBT PREVENTION	EXPANDED COVERAGE

State Has Active Legislation

State Does Not Have Active Legislation

The Health Care Value Hub ("the Hub") is proud to launch the 2024 Health Care Affordability Policy Snapshot ("Affordability Snapshot") which replaces the annual Healthcare Affordability Scorecard ("Scorecard"). The Affordability Snapshot provides legislators, consumer advocates, regulators and other stakeholders a tool to compare their state's health policies across other states.

The categories examined in this resource explore a variety of policy options that have previously appeared in the Scorecard, as well additional policies that impact health care affordability. Policies were selected based on whether they have the potential to impact health care affordability or access to health care at the state level, whether a reputable source was available for review, and whether evidence was current within the past ten years.

Policies were examined for whether they were active, implemented to a limited degree, or not active as of July 1, 2024. Sources for this information can be found in the downloadable Data and Source Document available on the <a href="Dashboard">Dashboard</a> page.

The Hub offers both online and hands-on support, with a staff dedicated to monitoring, translating, and disseminating evidence and connecting advocates, researchers, and policymakers to build communities and galvanize action around creating a patient-centered, high-value healthcare system. As a research-based organization, the Hub takes a comprehensive approach to improving affordability through policy analysis, translation, visualization, and collaborative engagement. We encourage advocates, legislators, and other stakeholders to share our findings to improve consumer health care affordability across the states.

# Curb Excess Prices in the System

#### **Premium Rate Review**

States can control excessive health insurance premium increases through premium rate review, where state insurance regulators scrutinize proposed rate hikes for the upcoming year to ensure that the increases are based on accurate data and realistic projections of health care costs and utilization. The Affordable Care Act (ACA) set standards for these efforts, and states meeting these standards are recognized by the Centers for Medicare and Medicaid Services (CMS) as having an effective rate review process. States may also establish the authority to approve or deny rate increases and incorporate affordability criteria into their evaluations. This section examines whether a state has an effective rate review program, as defined by CMS, the power to approve or deny rate increases, and if affordability criteria are integrated into the rate review process.

### **Health Care Spending Benchmarks**

Health spending benchmarks aim to limit annual health care spending growth by establishing a maximum limit, or "benchmark." Benchmarks may examine overall spending or spending for specific hospitals or insurers. If the benchmark is surpassed, the overseeing state entity will often collaborate with providers to curtail spending, and some states authorize the entity to mandate performance improvement plans or impose penalties. This section examines whether a state has established a benchmark, and if so, whether the state has statutory authority to enforce the benchmark.

### **Hospital Price Regulation**

This section assesses state efforts to reduce hospital service costs through reference-based pricing, global budgets, or a comparable program that regulates hospital pricing. Unlike reference-based benefits, which set a maximum allowed benefit for specified drugs or services, reference-based pricing establishes set service costs based on a predetermined reference rate. As of publication, each state that has implemented this model has set reimbursement as a multiple of the Medicare reimbursement rate.

Similarly, global budgeting involves setting a fixed prospective payment for a specified range of services over a defined period, rather than being paid for each service. By establishing a limit on annual spending, this model shifts the financial responsibility to providers and payers and encourages managing service delivery within the set budget. Some states have established state-specific insurance models which mirror select aspects of these strategies, which are also highlighted under "alternative hospital price regulation strategies."

### **Public Option**

A Public Option is a state-managed health insurance model designed to enhance competition and control costs through negotiated rates. States possess a degree of flexibility in designing these coverage options, resulting in variations in cost-containment measures and provisions related to network adequacy and reimbursement. This section highlights states that have an active Public Option and those with provider participation mandates to ensure consistent access to in-network providers.

Policy	Status as of July 1, 2024		Summary	
Premium Rate Review		Has an effective rate review process.	Maryland has the authority to approve or deny proposed premium rate increases in the individual, small, and large group markets. The state also has the authority to hold public hearings to solicit	
		Has the authority to modify or reject premium rate increases.	stakeholder engagement in the process.	
	$\otimes$	Does not incorporate affordability criteria into premium rate review.		
		Does not have health care spending benchmark for		
Health Care	$\otimes$	providers and/or insurers.*		
Spending Benchmarks	$\otimes$	Does not have a spending benchmark, with or without an enforcement mechanism.*		
		Has not implemented hospital reference-based pricing or		
	$\otimes$	rate-setting.	The Maryland Total Cost of Care (TCOC) model is the latest iteration of the "Maryland Model," which utilizes global budgets to curb excess health care costs. Under the current demonstration waiver, the	
Hospital Price Regulation		Has implemented hospital global budgets.	state assigns an annual global budget to all fifty-two acute care hospitals, covering all payers, including Medicaid, Medicare, commercial insurers, and the uninsured. Maryland was selected	
		Has implemented alternative hospital price regulation strategies.	participate in the "States Advancing All-Payer Health Equity Approaches and Development (AHEAD) Innovation Model," facilitated by the Centers for Medicare and Medicaid Services (CMS). Maryland is participating in the first cohort, which includes an 18-month pre-implementation period, from July 2024 – December 2025. The first performance year is expected to begin in January 2026.	
Public	$\otimes$	Does not have an active Public Option.		











# Improve Oversight, Accountability, and Transparency

### **Health Spending Oversight Entities**

Health Spending Oversight Entities monitor and track health care spending systematically, offering data and research support to ensure efficient resource use. While many states set population health priorities, few have established oversight entities with enforcement powers. This section examines whether a state has a health spending oversight entity reviewing primary care, hospital, or prescription drug spending, and if upper payment limits for prescription drugs have been implemented.

### **All-Payer or Multi-Payer Claims Database**

All-payer claims databases (APCDs) compile diverse health care data, that may include health, dental, and pharmacy claims from private insurers, state employee health programs, Medicare, and Medicaid. In instances where a database includes only some of these payers, it is referred to as a multi-payer claims database. Typically created through legislation, APCDs are often subject to state oversight and regulation. However, some claims databases have been voluntarily developed by independent entities, limiting oversight.

This section examines whether a state has an active all-payer or multi-payer claims database, if the database is facilitated and managed by the state or by third-party entities, if the data is free and accessible without institutional review board approval, and if the database is required to capture race and ethnicity demographic information.

### **Price Transparency**

This section evaluates state efforts to provide access to health care price data through a publicly available and easily accessible tool. To be credited, the tool must show negotiated prices for various services and be accessible without fees, IRB approval, or legislative restrictions. Additionally, this section reviews whether a state requires prescription drug price data to be reported to a state entity and if a state has another form of price transparency regulation.

### **Medical Debt Collection Regulations**

This section examines how a state regulates providers' ability to collect medical debt once it has been incurred. It reviews whether a state: prohibits providers from sending debts to collections while a patient is actively pursuing efforts to address the bill (e.g., appealing to insurance, applying for financial assistance, negotiating the bill, in a payment plan); prohibits spouses or other persons from being held liable for another adult's debt; limits collections' ability to garnish wages; prohibits collections from initiating home foreclosure; prohibits collections from initiating actions that would lead to an individual's arrest due to medical debt; prohibits collections from seizing a bank account.

Policy	Status as of July 1, 2024		Summary	
Health Spending Oversight Entity	•	Has a Prescription Drug Affordability Board reporting on prescription drug prices.  Enforces prescription drug prices through Upper Payment Limits.	Maryland's Prescription Drug Affordability Board studies the pharmaceutical supply chain, the out-of-pocket cost of drugs, and reviews possible policy options. The board also has the authority to set upper payment limits for prescription drugs purchased by state or local governments and government-affiliated hospitals/institutions.	
	<ul><li>⊗</li></ul>	Monitors and reports on hospital spending.  Does not monitor and report on primary care spending.	Maryland's Health Services Cost Review Commission, established in 1971, reviews hospital spending. Senate Bill 734 passed in 2022 requires the Maryland Health Care Commission to report annually on ways to improve access to primary care services with reporting beginning in December 2024.	
All-Payer or		Has a(n) all-payer or multi-payer claims database.  Database is operated by the state.	Maryland's APCD data is available by formal request and payment.	
Multi-Payer Claims Database		Database is operated by the state.  Database does not include access restrictions.  Database is required to capture demographic information.		
		Batabase to required to capture demographic information.		
		Has a price transparency tool showing negotiated rates.	The Maryland Health Care Commission's WeAreTheCost website shares the average negotiated prices	
Price Transparency	$\otimes$	Does not have a Prescription Drug price transparency reporting requirement.*	under private insurance and Medicaid for 24 common services.	
	$\otimes$	Does not have any other price transparency regulation.*		
Medical Debt Collection Regulations	•	Prohibits providers from sending debts to collections while patient is actively pursuing means to pay the bill. Prohibits other persons being held liable for another adult's medical debt.	Maryland prohibits hospitals from forcing the sale or foreclosure of a patient's primary residence to collect medical debt. However, if a hospital holds a lien on a patient's primary residence, the hospital may maintain its position as a secured creditor with respect to other creditors to whom the patient may owe a debt. The state prevents hospitals from garnishing wages from patients who qualify for free	
		Prohibits collections from initiating home lien or foreclosure due to medical debt.	or reduced-cost care. Hospitals in Maryland are also prohibited from taking action that may cause a court to issue a body attachment or an arrest warrant against a patient to collect on medical debts.	
		Exceeds federal wage garnishment protections.		
		Prohibits actions that would lead to an individual's arrest due to medical debt.		
	$\otimes$	Does not prohibit collections from initiating bank account seizure due to medical debt.		








State Has Active Policy or Program O Policy or Program Partially Implemented





# Address Consolidation and Promote Competition

#### **Consolidation Assessment and Authorization**

This section examines whether relevant parties are required by law or statute to notify the state of hospital consolidation transactions beyond the federal requirements, and whether the state has the authority to review these transactions; to approve, reject, or modify conditions of the transaction; and if consumer affordability or price growth are included in the review criteria

#### **Balance Bill Protections**

The federal No Surprises Act (NSA) protects patients from balance bills, which are unexpected costs from out-of-network providers. Under the federal legislation, patients receiving emergency care or who are unknowingly treated by out-of-network providers during an in-network procedure are only required to pay the innetwork cost-sharing amount for services provided. Effective January 1, 2022, the No Surprises Act applies to most health plans but not all care sites and services. States can legislate additional protections for balance bills not covered under the NSA, such as for ground ambulances, or services provided at urgent care locations, hospice facilities, and birthing centers.

### **Facility Fee Limits**

Facility fees are charges for services provided in outpatient and physician office settings that hospitals own. These fees increase the out-of-pocket costs for care and are becoming increasingly more common as the rate of health system consolidation has accelerated. This section explores whether a state prohibits facility fees under certain circumstances, if they have imposed regulations to protect consumers against out-of-pocket costs from facility fees, and if they require hospitals to report facility fee data.

### **Anti-Competitive Contract Provisions**

Anti-competitive contracting is a pattern of contracting between health care providers and insurers where one party gains unfair advantages over potential competitors. States can enact regulations that limit dominant health systems from abusing their market power in ways that increase prices. This section evaluates whether states prohibit four types of anti-competitive contracting practices in the health system:

- Most Favored Nation Clauses: Health systems agree not to offer lower prices to competing insurers, preventing them from offering the same service at a lower price. These provisions may allow insurers and providers to collude to raise prices.
- All-or-Nothing Clauses: Health systems require plans to contract with all providers in their system or none of them, even if those providers are low-value or high-cost.
- Non-Compete Clauses: Doctors are prohibited from working at competing hospitals within a certain distance for a certain period of time.
- Anti-Tiering or Anti-Steering Clauses: Insurers must place favored providers in higher tiers regardless of cost or quality (anti-tiering) and restrict directing patients to higher value care from competitors (anti-steering).

Policy	Status as of July 1, 2024		Summary
Consolidation Assessment & Authorization	consolidati Has author consolidati Includes co	ertain healthcare providers to notify the state of on transactions.  Fity to approve, set conditions, or disapprove on transactions.  Ensumer affordability and/or price growth in eria or approval conditions.	Maryland requires the Attorney General be notified of nonprofit health entity acquisitions, and has authority to approve, set conditions for, or disapprove transactions. Criteria include continued access to affordable care for communities affected by the transaction.
Balance Bill Protections	ambulance  Does not p	alance billing for out-of-network ground services.  brohibit balance billing for out-of-network specific facilities not included in the NSA.	Maryland has established balance bill protections that apply to public ground ambulance services. However, these protections only apply if the ambulance service provider obtains an assignment of benefits from the insured.
Facility Fee Limits	settings.  Does not h costs from	acility fees for specified procedures and/or care have codified protections against out-of-pocket facility fees.*  ospitals to report facility fee data.	Maryland prohibits providers from charging facility fees for telehealth, COVID-19 testing, and monoclonal antibodies services. Hospitals are required to report facility fee data on an annual basis.
Anti- Competitive Contract Provisions	<ul><li>No law res</li><li>No law res</li><li>provisions.</li></ul>	s limiting physician non-compete contract	Maryland prohibits Most Favored Nation clauses in contracts between insurers and healthcare providers, including hospitals and ambulatory surgical facilities. The law forbids clauses that ensure one plan gets more favorable reimbursement terms than another. Effective July 1, 2025, noncompete agreements for healthcare professionals working in direct patient care and earning \$350,000 or less annually will be void and unenforceable in Maryland.









## Make Out-of-Pocket Costs Affordable

### **Reduced Cost Sharing: Prescription Drugs**

This section examines whether states have passed legislation reduce the amount a consumer pays out-of-pocket for select prescriptions drugs including insulin, epinephrine, oral oncology medications and asthma inhalers. This section also examines state-level legislation prohibiting copay accumulator programs, which are payer strategies that limit the impact of manufacturer cost-sharing assistance programs on consumer out-of-pocket costs.

### Reduced Cost-Sharing: High Value Services

This section provides an overview of state efforts aimed at reducing consumer cost burdens for high-value services. Specifically, it identifies states which have enacted legislation mandating coverage without cost-sharing for: primary care services recommended by the United States Preventive Services Task Force (USPSTF); various cancer screening and diagnostic services; and annual mental health exams. It also evaluates state efforts to expand access to affordable maternal and reproductive health care by highlighting the states that mandate private insurers cover in-vitro fertilization, fertility preservation, doula services and abortion care. The section concludes with a review of whether a state has incorporated equity-focused initiatives in their state-regulated insurance design.

#### **Medical Debt Prevention**

This section reviews state laws aimed at preventing medical debt, including mandates for hospitals and health care providers to offer financial assistance policies, screen patients for insurance and charity care eligibility, and inform patients of charity care policies before collecting payment. It also assesses whether states have extended Medicaid benefits retroactively for 90 days; expanded general presumptive eligibility for Medicaid to all adults; prohibited short-term, limited duration health plans; and if the state has established annual reporting requirements on community benefit spending.

### **Expanded Coverage**

This section evaluates policies aimed at expanding access to and improving the affordability of health insurance, including whether a state has expanded Medicaid eligibility to adults with incomes up to 138% of the federal poverty level (FPL); authorized 12-month continuous Medicaid eligibility for all adults; extended postpartum Medicaid coverage to 12 months following delivery: established a Basic Health Plan; initiated a program providing state-funded premium subsidies for residents ineligible for Medicaid; explicitly authorizes coverage for gender-affirming care under Medicaid; has authorized the provision of Medicaid coverage to individuals transitioning from incarceration; and if the state has extended Medicaid coverage to include dental, hearing, and vision benefits, including eye exams and glasses, beyond what is deemed medically necessary following injury or surgery. Beyond these policy options, this section also reviews state efforts to extend coverage to children, pregnant residents, and non-pregnant adults regardless of immigration status. This includes waiving the five-year required waiting period for immigrant children and legally residing pregnant residents (the "five-year bar"); offering alternative coverage options regardless of citizenship status; and opting into the From-Conception-to-End-of-Pregnancy (FCEP) option under the Children's Health Insurance Program (CHIP), previously known as the CHIP Unborn Child option.

Policy	Status as of July 1, 2024	Summary
Reduced Cost-Sharing: Prescription Drugs	Does not prohibit copay accumulator programs.  Caps the price of insulin or diabetes supplies.	Maryland caps the out-of-pocket cost for a 30-day supply of prescription insulin at \$30.00, regardless of the amount or type of insulin needed. The state also limits the amount residents must pay for prescription drugs used to treat complex or chronic medical conditions, including multiple sclerosis and hepatitis C, by capping cost-sharing at \$150.00 for a 30-day supply of the specialty drug, and has
	Caps the price of other prescription drugs or medical devices (see notes).	passed separate legislation that caps cost-sharing for prescription drugs used to treat HIV or AIDS at
Reduced Cost-Sharing: High Value Services	<ul> <li>Mandates private insurers cover USPSTF recommended preventive services without cost-sharing.</li> <li>Does not waive or reduce cost-sharing for an annual mental health wellness exam in private health plans.</li> <li>Provides coverage and/or waives or reduces cost-sharing for select maternal and reproductive health services.</li> <li>Mandates coverage for some cancer screening services without cost-sharing.</li> <li>Insurance design includes cost-saving measures to mitigate health disparities.</li> </ul>	Maryland's Medicaid program is required to cover doula services for enrollees. The state also mandates that health benefit plans provide coverage for both in-vitro fertilization and fertility preservation. Additionally, all health benefit plans issued in Maryland must cover abortions and abortion -related services without cost-sharing.  Insurers in Maryland are required to provide coverage for breast cancer screenings predeductible and the following cancer examinations without cost-sharing: diagnostic breast examinations; supplemental breast examinations; and prostate cancer screenings, including digital rectal exam and a blood test.  All Value Plans on the Maryland Health Connection cover the full cost of insulin, glucometers, test strips, and routine diabetic care. Maryland also offers a Young Adult Health Coverage Subsidies pilot program for residents aged 18 to 37.
provide free or discounted care with set eligibility criteria		Maryland requires hospitals and ambulatory care facilities to provide free care to patients earning up to 200% FPL, offer discounted services to patients earning more than 200% FPL, and extend payment plans to patients earning between 200% and 500% FPL.









State Does Not Have an Active Policy or Program

\* No Source, or Limited Information Found

Policy	Status as of July 1, 2024		Summary	
		Expanded Medicaid income eligibility to 138% FPL.	Maryland Medicaid covers eye exams, but not eyeglasses, for adults; covers hearing aids and other hearing devices for adults; and offers some dental coverage for extraction, root canals, restorative (fillings and crowns), preventive, and diagnostic services, but does not cover dentures.	
Expanded Coverage — Medicaid	$\otimes$	Does not offer a basic health plan or other affordable coverage option for residents with incomes below 200% FPL.*		
	$\otimes$	Has not authorized 12-month continuous eligibility for adult Medicaid enrollees.	Maryland offers state-based premium subsidies for adults ages 18-37 with incomes up to 400% FPL through 2025.	
		Includes 12 months of postpartum care in Medicaid benefits.	Maryland has established statutory language ensuring that its Medicaid program includes gender-	
	$\otimes$	Does not provide select Medicaid services to justice-involved people up to 90 days before release.*	affirming care in the benefits package.	
		Medicaid policy does not explicitly include coverage for gender-affirming services.		
	<b>O</b>	Offers extensive dental, vision, or hearing coverage in Medicaid benefits.		
	$\otimes$	Does not offer state-based premium subsidies.		
		Offers coverage for lawfully residing immigrant children or pregnant people without a five-year bar.	Maryland provides post-pregnancy coverage to people regardless of immigration status.	
Expanded Coverage — Immigrant Coverage	$\otimes$	Covers pregnancy-related services through the CHIP "From-Conception-to-End-of-Pregnancy" (FCEP) Option.	In 2024 the state passed the Access to Care Act under which the state will apply for a 1332 federal waiver to allow undocumented immigrants to purchase insurance plans on the state-run Marketplace	
	$\otimes$	Does not offer an affordable coverage option for undocumented immigrant children.	starting in 2026.	
	0	Does not offer an affordable coverage option for undocumented immigrant adults.		













